With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

"The absence of a statistically significant benefit of adjuvant chemotherapy in the ASTER 70s trial underlines the persistent ...

In August 2025, Biocad conducted a study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth ...

Hernexeos is now approved for use in patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Despite significant advances in early detection, surgery, radiotherapy, and systemic treatment of breast cancer, late relapse ...